In the EGFRmut group, patients who had LM and who were treated with EGFR TKIs had shorter PFS (7.5 vs. 11.8 months) and OS (20.8 vs. 30.6 months) compared to patients without liver metastases [30]. The gene discussed is EGFR; the disease is lymphangioma.